Annals of thoracic surgery short reports · 2025
Outcomes Linked to 3N2+1N1 Sampling by Surgery Type: A Commission on Cancer Lung Cancer Quality Metric.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baskin Alison S, Tupper Haley I, Sarovar Varada, Santhakumar Jessica, Banks Kian C, Sun Angela, Wile Rachel, Barnes Katherine, Sakoda Lori C, Velotta Jeffrey B
Аннотация
BACKGROUND: In 2021, the Commission on Cancer implemented Standard 5.8 requiring lymph node sampling from ≥3 mediastinal and ≥1 hilar stations (3N2+1N1) during curative-intent lung cancer resections. Before Standard 5.8, sampling ≥10 lymph nodes was recommended. To date, the optimal nodal sampling strategy is still unknown, particularly for sublobar resections. We assessed 3N2+1N1 sampling patterns and potential associations with recurrence and mortality by resection type.
METHODS: In this multicenter retrospective study, we evaluated early-stage non-small cell lung cancer (NSCLC) patients who underwent lobectomy or sublobar resection (2009-2019). We calculated the proportion with 3N2+1N1 sampled. Using multivariable Cox regression, we assessed associations of 3N2+1N1 sampling with 1-year recurrence and 5-year overall mortality, stratified by lobectomy vs sublobar resection.
RESULTS: Among 2096 lobectomy patients, 43% had 3N2+1N1 sampling. In contrast, among 386 sublobar resection patients, 23% had 3N2+1N1. We found 3N2+1N1 sampling was not significantly associated with 1-year recurrence or 5-year mortality after lobectomy, but was associated with reduced 1-year recurrence (adjusted hazard ratio, 0.62; 95% CI, 0.39-0.98) after sublobar resection.
CONCLUSIONS: A minority of lobectomy and sublobar resection patients had 3N2+1N1 sampling. Although 3N2+1N1 sampling was not associated with improvements across all outcomes, our findings suggest that Standard 5.8 may be a meaningful step toward improved quality of lymph node evaluations in some patients.
METHODS: In this multicenter retrospective study, we evaluated early-stage non-small cell lung cancer (NSCLC) patients who underwent lobectomy or sublobar resection (2009-2019). We calculated the proportion with 3N2+1N1 sampled. Using multivariable Cox regression, we assessed associations of 3N2+1N1 sampling with 1-year recurrence and 5-year overall mortality, stratified by lobectomy vs sublobar resection.
RESULTS: Among 2096 lobectomy patients, 43% had 3N2+1N1 sampling. In contrast, among 386 sublobar resection patients, 23% had 3N2+1N1. We found 3N2+1N1 sampling was not significantly associated with 1-year recurrence or 5-year mortality after lobectomy, but was associated with reduced 1-year recurrence (adjusted hazard ratio, 0.62; 95% CI, 0.39-0.98) after sublobar resection.
CONCLUSIONS: A minority of lobectomy and sublobar resection patients had 3N2+1N1 sampling. Although 3N2+1N1 sampling was not associated with improvements across all outcomes, our findings suggest that Standard 5.8 may be a meaningful step toward improved quality of lymph node evaluations in some patients.